Cargando…
Tricyclic antidepressants and headaches: systematic review and meta-analysis
Objective To evaluate the efficacy and relative adverse effects of tricyclic antidepressants in the treatment of migraine, tension-type, and mixed headaches. Design Meta-analysis. Data sources Medline, Embase, the Cochrane Trials Registry, and PsycLIT. Studies reviewed Randomised trials of adults re...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958257/ https://www.ncbi.nlm.nih.gov/pubmed/20961988 http://dx.doi.org/10.1136/bmj.c5222 |
_version_ | 1782188311947771904 |
---|---|
author | Jackson, Jeffrey L Shimeall, William Sessums, Laura DeZee, Kent J Becher, Dorothy Diemer, Margretta Berbano, Elizabeth O’Malley, Patrick G |
author_facet | Jackson, Jeffrey L Shimeall, William Sessums, Laura DeZee, Kent J Becher, Dorothy Diemer, Margretta Berbano, Elizabeth O’Malley, Patrick G |
author_sort | Jackson, Jeffrey L |
collection | PubMed |
description | Objective To evaluate the efficacy and relative adverse effects of tricyclic antidepressants in the treatment of migraine, tension-type, and mixed headaches. Design Meta-analysis. Data sources Medline, Embase, the Cochrane Trials Registry, and PsycLIT. Studies reviewed Randomised trials of adults receiving tricyclics as only treatment for a minimum of four weeks. Data extraction Frequency of headaches (number of headache attacks for migraine and number of days with headache for tension-type headaches), intensity of headache, and headache index. Results 37 studies met the inclusion criteria. Tricyclics significantly reduced the number of days with tension-type headache and number of headache attacks from migraine than placebo (average standardised mean difference −1.29, 95% confidence interval −2.18 to −0.39 and −0.70, −0.93 to −0.48) but not compared with selective serotonin reuptake inhibitors (−0.80, −2.63 to 0.02 and −0.20, −0.60 to 0.19). The effect of tricyclics increased with longer duration of treatment (β=−0.11, 95% confidence interval −0.63 to −0.15; P<0.0005). Tricyclics were also more likely to reduce the intensity of headaches by at least 50% than either placebo (tension-type: relative risk 1.41, 95% confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to 2.62) or selective serotonin reuptake inhibitors (1.73, 1.34 to 2.22 and 1.72, 1.15 to 2.55). Tricyclics were more likely to cause adverse effects than placebo (1.53, 95% confidence interval 1.11 to 2.12) and selective serotonin reuptake inhibitors (2.22, 1.52 to 3.32), including dry mouth (P<0.0005 for both), drowsiness (P<0.0005 for both), and weight gain (P<0.001 for both), but did not increase dropout rates (placebo: 1.22, 0.83 to 1.80, selective serotonin reuptake inhibitors: 1.16, 0.81 to 2.97). Conclusions Tricyclic antidepressants are effective in preventing migraine and tension-type headaches and are more effective than selective serotonin reuptake inhibitors, although with greater adverse effects. The effectiveness of tricyclics seems to increase over time. |
format | Text |
id | pubmed-2958257 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-29582572010-10-28 Tricyclic antidepressants and headaches: systematic review and meta-analysis Jackson, Jeffrey L Shimeall, William Sessums, Laura DeZee, Kent J Becher, Dorothy Diemer, Margretta Berbano, Elizabeth O’Malley, Patrick G BMJ Research Objective To evaluate the efficacy and relative adverse effects of tricyclic antidepressants in the treatment of migraine, tension-type, and mixed headaches. Design Meta-analysis. Data sources Medline, Embase, the Cochrane Trials Registry, and PsycLIT. Studies reviewed Randomised trials of adults receiving tricyclics as only treatment for a minimum of four weeks. Data extraction Frequency of headaches (number of headache attacks for migraine and number of days with headache for tension-type headaches), intensity of headache, and headache index. Results 37 studies met the inclusion criteria. Tricyclics significantly reduced the number of days with tension-type headache and number of headache attacks from migraine than placebo (average standardised mean difference −1.29, 95% confidence interval −2.18 to −0.39 and −0.70, −0.93 to −0.48) but not compared with selective serotonin reuptake inhibitors (−0.80, −2.63 to 0.02 and −0.20, −0.60 to 0.19). The effect of tricyclics increased with longer duration of treatment (β=−0.11, 95% confidence interval −0.63 to −0.15; P<0.0005). Tricyclics were also more likely to reduce the intensity of headaches by at least 50% than either placebo (tension-type: relative risk 1.41, 95% confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to 2.62) or selective serotonin reuptake inhibitors (1.73, 1.34 to 2.22 and 1.72, 1.15 to 2.55). Tricyclics were more likely to cause adverse effects than placebo (1.53, 95% confidence interval 1.11 to 2.12) and selective serotonin reuptake inhibitors (2.22, 1.52 to 3.32), including dry mouth (P<0.0005 for both), drowsiness (P<0.0005 for both), and weight gain (P<0.001 for both), but did not increase dropout rates (placebo: 1.22, 0.83 to 1.80, selective serotonin reuptake inhibitors: 1.16, 0.81 to 2.97). Conclusions Tricyclic antidepressants are effective in preventing migraine and tension-type headaches and are more effective than selective serotonin reuptake inhibitors, although with greater adverse effects. The effectiveness of tricyclics seems to increase over time. BMJ Publishing Group Ltd. 2010-10-20 /pmc/articles/PMC2958257/ /pubmed/20961988 http://dx.doi.org/10.1136/bmj.c5222 Text en © Jackson et al 2010 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Research Jackson, Jeffrey L Shimeall, William Sessums, Laura DeZee, Kent J Becher, Dorothy Diemer, Margretta Berbano, Elizabeth O’Malley, Patrick G Tricyclic antidepressants and headaches: systematic review and meta-analysis |
title | Tricyclic antidepressants and headaches: systematic review and meta-analysis |
title_full | Tricyclic antidepressants and headaches: systematic review and meta-analysis |
title_fullStr | Tricyclic antidepressants and headaches: systematic review and meta-analysis |
title_full_unstemmed | Tricyclic antidepressants and headaches: systematic review and meta-analysis |
title_short | Tricyclic antidepressants and headaches: systematic review and meta-analysis |
title_sort | tricyclic antidepressants and headaches: systematic review and meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958257/ https://www.ncbi.nlm.nih.gov/pubmed/20961988 http://dx.doi.org/10.1136/bmj.c5222 |
work_keys_str_mv | AT jacksonjeffreyl tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis AT shimeallwilliam tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis AT sessumslaura tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis AT dezeekentj tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis AT becherdorothy tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis AT diemermargretta tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis AT berbanoelizabeth tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis AT omalleypatrickg tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis |